Publications

Publications Co-Authored by Lundbeck Scientists

Our commitment to science is reflected in our track record of publications. Here are the most recent publications co-authored by Lundbeck scientists.

Article	Product	Authors	Publication links	Year
A Randomized, Open‑Label, Multiple‑Dose, Parallel‑Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2‑Month Long‑Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder	Aripiprazole	Harlin M, Yildirim M, Such P, Madera-McDonough J, Jan M, Jin N, Watkin S, Larsen F	Read publication	2023
Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: protocol for RESOLUTION – a phase 4, multi-national, randomised, double-blind, placebo-controlled study	Eptinezumab	Jensen R, Schytz H, Tassorelli C, Terwindt G, Carlsen L, Mittoux A, Osterberg O, Lipton R, Tepper S, Blumenfeld A, Lundqvist C,	Read publication	2023
Alternative Indirect Treatment Comparisons for Eptinezumab in Episodic and Chronic Migraine Prevention	Eptinezumab	Fawsitt C, Thom H, Regnier S, Lee X, Kymes S, Vase L	Read publication	2023
An exploratory database study of factors influencing the continuation of brexpiprazole treatment (prescription) in patients with schizophrenia using information from psychiatric electronic medical records processed with natural language processing system	Brexpiprazole	Iyo M, Akiyoshi H, Sekine D, Shibasaki Y, Mamiya N	Read publication	2023
Aripiprazole plasma concentrations delivered from two 2-month long-acting injectable formulations: an indirect comparison	Aripiprazole	Fitzgerald H, Saklad SR, Chepke C, Harlin M, Larsen F, Chumki S, Such P, Yildirim M, Panni M, Madera-McDonough J	Read publication	2023
Considerations when selecting an antidepressant: a narrative review for primary care providers treating adults with depression	Vortioxetine	Montano BC, Jackson CW, Vanacore D, Weisler R	Read publication	2023
Disease-Specific Quality of Life Measures Mapped to the EQ-5D in Patients with Migraine: A Post Hoc Analysis of the DELIVER Trial	Eptinezumab	Jönsson L, Regnier SA, Kymes S, Awad SF,Talon B, Lee, XY, Goadsby P	Read publication	2023
Does ethnicity impact CYP2D6 genotype–phenotype relationships?	Vortioxetine	Frederiksen T, Areberg J, Schmidt E, Stage TB and Brøsen K	Read publication	2023
Early Clinical Experience With Eptinezumab: Results of a Retrospective Observational Study of Patient Response in the United States	Eptinezumab	Starling A, Kymes S, Asher D, Soni-Brahmbhatt S, Karnik-Henry M	Read publication	2023
Effectiveness of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: US Cohort Results From the Global RELIEVE Study	Vortioxetine	Mattingly G, Brunner E, Chrones L, Lawrence DF, Simonsen K, Ren H	Read publication	2023
Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer's disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea	Vortioxetine	Cumbo E, Adair M, Åstrom DO, Christensen MC	Read publication	2023
Efficacy and Safety of Eptinezumab for Migraine Prevention in Patients With Documented Prior Preventive Treatment Failures: Subgroup Analysis of the Randomized, Placebo-Controlled DELIVER Trial	Eptinezumab	Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen L, Josiassen MK, Phul R, Sperling B	Read publication	2023
Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures	Eptinezumab	Goadsby PJ, Barbanti P, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B	Read publication	2023
Eptinezumab Improved Patient-Reported Outcomes in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2	Eptinezumab	Starling AJ, Cowan R, Cady R	Read publication	2023
Eptinezumab Improved Patient-Reported Outcomes in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2	Eptinezumab	Starling AJ, Buse D, Cowan R, Diener HC, Marmura MJ, Hirman J, Brevig T, Freeman E, Cady R	Read publication	2023
The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study	Eptinezumab	Rasmussen N, Deligianni C, Christensen C, Karlsson W, Al-Khazali H, Van de Casteele T, Granhall C, Amin F, Ashina M	Read publication	2023
Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies	Vortioxetine	Mattingly GW, Necking O, Schmidt SN, Reines E, Ren H	Read publication	2023
Mental health diagnoses and services utilization vary by wage level	Vortioxetine	Sherman B, Lawrence D, Kuharic M, Chrones L, Patel S, Touya M	Read publication	2023
Patient Preferences for Attributes of Advanced Migraine Prevention Medications: Findings From a Discrete Choice Experiment	Eptinezumab	Schwedt T, Martin A, Kymes S, Talon B, Lee X, Cady R, Asher D, Karnik-Henry M, Mulvihill E, Bates D, Beusterien K	Read publication	2023
Relationships Between Headache Frequency, Disability, and Disability-Related Unemployment Among Adults with Migraine	Eptinezumab	Shapiro R, Martin A, Bhardwaj S, Thomson H, Maculaitis M, Anderson C, Kymes S	Read publication	2023
Safety and effectiveness of vortioxetine for major depressive disorder: real-world evidence from a population-based study in South Korea	Vortioxetine	Moon SW, Kim JW, Kim DH, Lee KY, Reines EH, Lee M, Park YJ	Read publication	2023
Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary Analysis of Outcomes in Adult Patients with Bipolar I Disorder in a Randomized, Parallel-Arm, Pivotal Study	Aripiprazole	McIntyre RS, Larsen F, Madera-McDonough J, Such P, Yildirim M, Zhang Z, Harlin M	Read publication	2023
Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability	Vortioxetine	Adair M, Christensen MC, Florea I, Loft H, Fagiolini A	Read publication	2023

Article	Product	Authors	Publication links	Year
A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder	Vortioxetine	Bose R, Hamdani SU, Minhas FA, Herr KJ	Read publication	2022
A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia	N/A	Meyer-Lindenberg A, Nielsen J, Such P, Lemming O, Zambori J, Buller R, von der Goltz C	Read publication	2022
A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of L-Dopa-induced dyskinesia	N/A	Calabrese V, Picconi B, Heck N, Campanelli F, Natale G, Marino G, Sciaccaluga M, Ghiglieri V, Tozzi A, Anceaume E, Cuoc E, Caboche J, Conquet F, Calabresi P, Charvin D	Read publication	2022
A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease	N/A	Rascol O, Medori R, Baayen C, Such P, Meulien D	Read publication	2022
Activity-State Dependent Reversal of Ketamine-Induced Resting State EEG Effects by Clozapine and Naltrexone in the Freely Moving Rat	N/A	Bowman C, Richter U, Jones C, Agerskov C, Frisch Herrik K	Read publication	2022
Adherence to, and persistence of, antidepressant therapy in patients with major depressive disorder: results from a population-based study in Italy	Vortioxetine	Di Nicola M, Dell’Osso B, Peduto I, Cipelli R, Pugliese AC, Signorelli MS, Ventriglio A, Martinotti G	Read publication	2022
Advancing 89Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody - The choice of chelator is essential	N/A	Wuensche T, Stergiou N, Mes I, Verlaan M, Schreurs M, Kooijman E, Janssen B, Windhorst A, Jensen A, Asuni A, Bang-Andersen B, Beaino W, Dongen G, Vugts D	Read publication	2022
An app-based digit symbol substitution test for assessment of cognitive deficits in adults with major depressive disorder: evaluation study	Vortioxetine	McIntyre RS, Lipsitz O, Rodrigues NB, Subramaniapillai M, Nasri F, Lee Y, Fehnert B, King J, Chrones L, Kratiuk K, Uddin S, Rosenblat JD, Mansur RB, McCue M	Read publication	2022
Antidepressant prescription for major depressive disorder: results from a population-based study in Italy	Vortioxetine	Dell’Osso B, Di Nicola M, Cipelli R, Peduto I, Pugliese AC, Signorelli M, Ventriglio A, Martinotti G	Read publication	2022
Antipsychotic treatment patterns in Alzheimer's disease patients with agitation: a cohort study using the UK clinical practice research datalink	Brexpiprazole	Tran CT, Bøg M, CollingsSL, Johnson M, Qizilbash N, Lind S, Baker RA, Jørgensen KT	Read publication	2022
Apo and ligand-bound high resolution Cryo-EM structures of the human Kv3.1 reveal a novel binding site for positive modulators	N/A	Botte M, Huber S, Bucher D, Klint J, Rodríguez D, Tagmose L, Chami M, Cheng R, Hennig M, Rahman W	Read publication	2022
Association between baseline cognitive symptoms and the subsequent presenteeism and global function in patients with major depressive disorder	Vortioxetine	Watanabe K, Marumoto T, Ge H, Moriguchi Y, Fujikawa K, Fernandez JL	Read publication	2022
Association between CYP2D6 metabolizer status and vortioxetine exposure and treatment switching: a retrospective, naturalistic cohort study using therapeutic drug monitoring data from 640 patients	Vortioxetine	Frederiksen T, Smith RL, Jukic MM, Molden E	Read publication	2022
Behavioral encoding across timescales by region-specific dopamine dynamics	N/A	Jørgensen S,Ejdrup A, Lycas M, Posselt L, Tian L, Dreyer J, Herborg F, Sørensen A, Gether U	Read publication	2022
Changes in Acute Headache Medication Use Among Patients With Chronic Migraine: Subanalysis of PROMISE-2	Eptinezumab	Cowan RP, Marmura MJ, Diener HC, Starling A, Schim J, Hirman J, Brevig T, Cady R	Read publication	2022
Characterizing mood disorders in the AFFECT study: a large, longitudinal, and phenotypically rich genetic cohort in the US	N/A	Dalby M, Vitezic M, Plath N, Hammer-Helmich L, Jiang Y, Tian C, Dhamija D, Wilson C, Hinds D, 23andMe Research Team, Sullivan P, Buckholtz J, Smoller J	Read publication	2022
Characterizing Mood Disorders in the AFFECT study: A Large, Longitudinal, and Phenotypically Rich Genetic Cohort in the US	N/A	Dalby M, Vitezic M, Plath N, Hammer-Helmich L, Jiang Y, Tian C, Dhamija D, Wilson C, Hinds D, 23andMe Research Team, Sullivan P, Buckholtze J, Smollerg J	Read publication	2022
Characterizing primary care for patients with major depressive disorder using electronic health records of a US-based healthcare provider	Vortioxetine	Larson S, Nemoianu A, Lawrence DF, Troup M, Gionfriddo M, Pousti B, Sun H, Riaz F, Wagner E, Chrones L, Touya M	Read publication	2022
Chronic Stress Induces Hippocampal Mitochondrial Damage in APPPS1 Model Mice and Wildtype Littermates	N/A	Clement A, Madsen M, Kastaniegaard K, Wiborg O, Asuni A, Stensballe A	Read publication	2022
Development and validation of a novel model for characterizing migraine outcomes within real-world data	Eptinezumab	Hindiyeh NA, Riskin D, Alexander K, Cady R, Kymes S	Read publication	2022
Disease progression in Multiple System Atrophy ─ Novel modelling framework and predictive factors	N/A	Kühnel L, Raket L, Åström D, Berger A-K, Helbech Hansen I, Krismer F, Wenning G, Seppi K, Poewe W, Molinuevo JL on behalf of the EMSA-SG natural history study investigators	Read publication	2022
Diseases prevalent before major depressive disorder diagnosis: an exploratory nested case–control study using health insurance-based claims data	Vortioxetine	Cho Y, Mishiro I, Akaki T, Akimoto T, Fujikawa K	Read publication	2022
Distal kinetic deuterium isotope effect: Phenyl ring deuteration attenuates N-demethylation of Lu AF35700	N/A	Jensen K, Christoffersen C, Didriksen M, Jørgensen M	Read publication	2022
Durability of the Clinical Benefit of Droxidopa for Treatment of Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment	Droxidopa	R Hauser, Gorny S, Hewitt, LA, Lindsten A, Kymes S, Favit A, Isaacson S	Read publication	2022
Early Response to Eptinezumab Indicates High Likelihood of Continued Response in Patients with Chronic Migraine	Eptinezumab	Buse DC, Winner PK, Charleston LC, Hirman J, Cady R, Brevig T	Read publication	2022
Effectiveness and safety of Vortioxetine for major depressive disorder in real-world clinical practice: results from the single-arm RELIEVE China study	Vortioxetine	Wang G, Xiao L, Ren H, Simonsen K, Ma J, Xu X, Guo P, Wang Z, Bai L, Reines EH, Hammer-Helmich L	Read publication	2022
Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study	Vortioxetine	Almeida SS, Christensen MC, Simonsen K, Adair M	Read publication	2022
Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: results of the RECONNECT study	Vortioxetine	Christensen MC, Schmidt S, Grande I	Read publication	2022
Effectiveness of vortioxetine in patients with major depressive disorder in real-world clinical practice in Italy: results from the RELIEVE study	Vortioxetine	De Filippis S, Pugliese A, Christensen MC, Rosso G, Di Nicola M, Simonsen K, Ren H,	Read publication	2022
Effectiveness of vortioxetine in patients with major depressive disorder in real-world clinical practice: French cohort results from the global RELIEVE study	Vortioxetine	Polosan M, Rabbani M, Christensen MC, Simonsen K, Ren H	Read publication	2022
Effectiveness of vortioxetine in patients with major depressive disorder in real-world clinical practice: results of the RELIEVE study	Vortioxetine	Mattingly G, Ren H, Christensen MC, Katzman MA, Polosan M, Simonsen K, Hammer-Helmich L	Read publication	2022
Effects of brexpiprazole on functioning in patients with schizophrenia: post hoc analysis of short- and long-term studies	Brexpiprazole	Correll CU, Shi L, Therrien F, MacKenzie E, Meehan SR, Weiss C, Hefting N, Hobart M	Read publication	2022
Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study	Eptinezumab	Barbanti P, Goadsby PJ, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B	Read publication	2022
Efficacy and safety of eptinezumab for migraine prevention in patients with 2–4 prior preventive treatment failures: a randomized, double-blind, placebo-controlled, phase 3b study	Eptinezumab	Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen L, Josiassen MK, Phul R, Sperling B	Read publication	2022
Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2	Eptinezumab	Ashina M, McAllister P, Cady R, Hirman J, Ettrup A	Read publication	2022
Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness	Vortioxetine	Baldwin DS, Necking O, Schmidt SN, Ren H, Reines EH	Read publication	2022
Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: a post hoc analysis of four clinical studies	Brexpiprazole	Katzman M, Therrien F, MacKenzie E, Wang F, de Jong-Laird A, Boucher M	Read publication	2022
Emotional blunting in patients with depression. Part I: clinical characteristics	Vortioxetine	Christensen MC, Ren H, Fagiolini A	Read publication	2022
Emotional blunting in patients with depression. Part II: relationship with functioning, well‑being, and quality of life	Vortioxetine	Christensen MC, Ren H, Fagiolini A	Read publication	2022
Emotional blunting in patients with depression. Part III: relationship with psychological trauma	Vortioxetine	Christensen MC, Ren H, Fagiolini A	Read publication	2022
Epidemiology and treatment utilization for Canadian patients with migraine: a literature review	Eptinezumab	Graves E, Gerber B, Berrigan P, Shaw E, Cowling T, Ladouceur MP, Bougie J,	Read publication	2022
Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies	Eptinezumab	Baker B, Shen V, Cady R, Ettrup A, Larsen F	Read publication	2022
Eptinezumab for migraine prevention in patients 50 years or older	Eptinezumab	Martin V, Tassorelli C, Ettrup A, Hirman J, Cady R	Read publication	2022
Eptinezumab Treatment Initiated During a Migraine Attack is Associated with Meaningful Improvement in Patient-Reported Outcome Measures: Secondary Results From the Randomized Controlled RELIEF Study	Eptinezumab	McAllister P, Winner PK, Ailani J, Buse DC, Lipton RB, Chakhava G, Josiassen MK, Lindsten A, Mehta L, Ettrup A, Cady R	Read publication	2022
Estimating the In Vivo Function of CYP2D6 Alleles through Population Pharmacokinetic Modelling of Brexpiprazole	Brexpiprazole	Frederiksen T, Areberg J, Raoufinia A, Schmidt E, Bjerregaard Stage T, Brøsen K	Read publication	2022
Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention	Eptinezumab	Lipton R, Goadsby P, Dodick D, McGinley J, Houts C, Wirth RJ, Kymes S, Ettrup A, Østerberg O, Cady R, Ashina M, Buse D	Read publication	2022
Exploring life engagement from the perspective of patients with major depressive disorder: a study using patient interviews	Brexpiprazole	Therrien F, Meehan S, Weiss C, Dine J, Brown T, MacKenzie E	Read publication	2022
Further validation of the THINC-it tool and extension of the normative data set in a study of n = 10.019 typical controls	N/A	Dalby M, Annas P, Harrison JE	Read publication	2022
Health-related quality of life over 6 months in patients with major depressive disorder who started antidepressant monotherapy	Vortioxetine	Noto S, Wake M, Mishiro I, Hammer-Helmich L, Ren H, Moriguchi Y, Fujikawa K, Fernandez J	Read publication	2022
Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2	Eptinezumab	Martin V, Nagy J, Janelidize M, Giorgadze G, Hirman J, Cady R, Mehta L., Buse D,	Read publication	2022
Impact of depression onset and treatment on the trend of annual medical costs in Japan: an exploratory, descriptive analysis of employer-based health insurance claims data	Vortioxetine	Cho Y, Mishiro I, Fujimoto S, Nakajima T	Read publication	2022
Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data	Vortioxetine	Touya M, Lawrence D, Kangethe A, Chrones L, Evangelatos T, Polson M	Read publication	2022
Indirect Meta-Analysis of Brexpiprazole Versus Aripiprazole in the Acute Treatment of Schizophrenia	Brexpiprazole	Seifritz E, Friede M, Schnitker J	Read publication	2022
Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials	Eptinezumab	Anderson C, Brunner E, Cady R, Hirman J, Ogbru A, McGill L, Schim J	Read publication	2022
Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab	Eptinezumab	Blumenfeld A, Ettrup A, Hirman J, Ebert B, Cady R	Read publication	2022
Lu AG64066 for Tourette Syndrome in adults.	N/A	Mueller-Vahl K; TBD	Read publication	2022
Measuring Dose-Related Efficacy of Eptinezumab for Migraine Prevention: Post Hoc Analysis of PROMISE-1 and PROMISE-2	Eptinezumab	Apelian R, Boyle L, Hirman J, Asher D	Read publication	2022
Mental healthcare resource utilization following initiation of aripiprazole 400mg long-acting injectable: a retrospective real-world study	Aripiprazole	Waters HC, Touya M, Wee SN, Ng M, Thadani S, Surendran S, Rentería M, Rush AJ, Patel R, Sarkar J, Fitzgerald HM, Chen M, Han X	Read publication	2022
Mobile app to enhance patient activation and patient-provider communication in major depressive disorder management: collaborative, randomized controlled pilot study	Vortioxetine	McCue M, Blair C, Fehnert B, King J, Cormack F, Sarkey S, Eramo A, Kabir C, Khatib R, Kemp D	Read publication	2022
Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study	Eptinezumab	Cady R, Lipton R, Buse D, Josiassen MK, Lindsten A, Ettrup A	Read publication	2022
Patient preference for early onset of efficacy of preventive migraine treatments	Eptinezumab	Ailani J, Winner P, Hartry A, Brevig T, Bøg M, Blædel Lassen A, Marsh K, Cutts K, Le Lay A	Read publication	2022
Patient-centricity and sensitivity to change of the unified MSA rating scale subitems: a data-driven analysis	N/A	Krismer F, Seppi K, Jönsson L, Åström D, Berger A-K, Simonsen J, Wenning G, Poewe W on behalf of EMSA-SG NHS Investigatorsa, Rasagiline-for-MSA investigatorsa	Read publication	2022
Patient-Identified Burden and Unmet Needs in Patients With Cluster Headache: An Evidence-Based Qualitative Literature Review	Eptinezumab	Freeman E, Adair M, Beeler D, Casper R, Herman MP, Reeves D, Reinsch S	Read publication	2022
Patient-reported outcome measures for life engagement in mental health: a systematic review	Brexpiprazole	McIntyre RS, Ismail Z, Watling CP, Weiss C, Meehan SR, Oberdhan D, Musingarimi P, Thase ME	Read publication	2022
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials	Eptinezumab	Lipton RB, Charleston L, Tassorelli C, Brevig T, Hirman J, Cady R	Read publication	2022
PET as a translational tool in drug development for Neuroscience compounds	Vortioxetine	Varrone A, Bundgaard C, Bang-Andersen B	Read publication	2022
PET as a translational tool in drug development for Neuroscience compounds	N/A	Varrone A, Bundgaard C, Bang-Andersen B	Read publication	2022
Polygenic heterogeneity in antidepressant treatment and placebo response	Vortioxetine	Nøhr AK, Forsingdal A, Moltke I, D. Howes OD, Vitezic M, Albrechtsen A, Dalby M	Read publication	2022
Population Pharmacokinetic Modeling and Exposure-Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia	Aripiprazole	Wang X, Raoufinia A, Bihorel S, Passarell J, Mallikaarjun S, Phillips L	Read publication	2022
Practical advice for primary care clinicians on the safe and effective use of vortioxetine for patients with major depressive disorder (MDD)	Vortioxetine	Montano B, Jackson C, Vanacore D, Weisler R	Read publication	2022
Prediction of residual cognitive disturbances by early response of depressive symptoms to antidepressant treatments in patients with major depressive disorder	Vortioxetine	Sumiyoshi T, Hoshino T, Mishiro I, Hammer-Helmich L, Ge H, Moriguchi Y, Fujikawa K, Fernandez J	Read publication	2022
Psychometric Validation of a Patient-Reported Single-Item Assessment of “Good Day Bad Day” in a Neurogenic Orthostatic Hypotension Population Treated With Droxidopa	Droxidopa	François C, Kymes S, Hewitt LA, Germain N, Majewska R, Taieb V	Read publication	2022
Psychometric Validation of a Patient-Reported Single-Item Assessment of “Good Day Bad Day” in a Neurogenic Orthostatic Hypotension Population Treated With Droxidopa	Droxidopa	Francois C, Germain N, Majewska R, Taieb V, Hewitt LA, Kymes	Read publication	2022
Rapid Resolution of Migraine Symptoms After Initiating the Preventive Treatment Eptinezumab During a Migraine Attack: Results from the Randomized RELIEF Trial	Eptinezumab	Ailani J, McAllister P, Winner PK Chakhava G, Josiassen MK, Lindsten A, Sperling B, Ettrup A, Cady R	Read publication	2022
Readmissions, Costs, and Predictors of Time to Outpatient Follow-Up After Discharge Among Medicaid Beneficiaries Utilizing Oral versus Long-Acting Injectable Antipsychotics in Bipolar Disorder or Schizophrenia	Aripiprazole	Tidmore LM; Keast SL; Waters HC; Pareja KL; Cothran T; Skrepnek GH	Read publication	2022
Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects	Vortioxetine	Papalexi E, Galanopoulos A, Kontis D, Markopoulou M, Balta G, Karavelas E, Panagiotidis P, Vlachos T, Ettrup A	Read publication	2022
Reduction in Migraine-Associated Burden After Eptinezumab Treatment in Patients With Chronic Migraine	Eptinezumab	McAllister P, Kudrow D, Cady R, Hirman J, Ettrup A	Read publication	2022
Remote Assessment of Disease and Relapse in Major Depressive Disorder (RADAR-MDD): Recruitment and retention in a longitudinal remote measurement study	N/A	Matcham F, Leightley D, Siddi S, Lamers F, White KM, Annas P, de Girolamo G, Difrancesco S, Haro JM, Horsfall M, Ivan A, Lavelle G, Li Q, Lombardini F, Mohr DC, Narayan V, Oetzmann C, Penninx BWJH, Simblett S, Wykes T, PAB member, Brasen C, Myin-Germeys I, Rintala A, Dobson R, Folarin A, Ranjan Y, Cummins N, Manyakov N, Vairavan S, Hotopf M, on behalf of the RADAR-CNS consortium	Read publication	2022
Residual cognitive and psychosocial functional impairment in outpatients in Greece who responded to conventional antidepressant monotherapy treatments for major depressive disorder (MDD)	Vortioxetine	Papalexi E, Galanopoulos A, Roukas D, Argyropoulos I, Michopoulos I, Douzenis A, Gkolia I, Fotiadis P, Kontis, Zervas IM	Read publication	2022
Risk of major depressive disorder in adolescent and young adult cancer patients in Japan	Vortioxetine	Akechi T, Mishiro I, Fujimoto S	Read publication	2022
Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies	Eptinezumab	Pozo-Rosich P, Dodick D, Ettrup A, Hirman J, Cady R	Read publication	2022
The Economic Burden of Post-Traumatic Stress Disorder in the United States from a Societal Perspective	Brexpiprazole	Davis L, Schein J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Urganus A, Guerin A, Lefebvre P, Houle C	Read publication	2022
The effect of combined dexmedetomidine and isoflurane anaesthesia on visually evoked responses in rats – an electrophysiological study	N/A	Østergaard F, Skoven CS, Laursen B, Dyrby T, Wade A	Read publication	2022
The effect of combined dexmedetomidine and isoflurane anaesthesia on visually evoked responses in rats – an electrophysiological study	N/A	Østergaard F, Laursen B, Christensen K et al	Read publication	2022
The Motivation and Energy Inventory (MEI): Analysis of the clinically relevant response threshold in patients with major depressive disorder and emotional blunting using data from the COMPLETE study	Vortioxetine	Christensen MC, Adair M, Loft H, McIntyre R	Read publication	2022
The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach	Aripiprazole	Correll C, Chepke C, Gionfriddo P, Parks J, Foxworth P, Basu A, Brister T, Brown D, Clarke C, Hassoun Y	Read publication	2022
Therapeutic potential of vortioxetine for anhedonia-like symptoms in depression: a post hoc analysis of data from a clinical trial conducted in Japan	Vortioxetine	Watanabe K, Fujimoto S, Marumoto T, Kitagawa T, Ishida K, Nakajima T, Moriguchi Y, Fujikawa K, Inoue T	Read publication	2022
Townsend et al. Antipsychotic-Related Stigma and the Impact on Treatment Choices: A Systematic Review and Framework Synthesis	Brexpiprazole	Townsend M, Houle C, Mose TN, Pareja K, Waters H, Brubaker M, Buchanan-Hughes A, Worthington E, Pritchett D	Read publication	2022
Treatment Discontinuation Among Patients with Schizophrenia Treated with Brexpiprazole and Other Oral Atypical Antipsychotics in Japan: A Retrospective Observational Study	Brexpiprazole	Hishimoto A, Yasui-Fukukori N, Sekine D, Matsukawa M, Yamada S	Read publication	2022
Validation and functional relevance of the short form of the perceived deficits questionnaire for depression for Japanese patients with major depressive disorder	Vortioxetine	Sumiyoshi T, Uchida H, Watanabe K, Oosawa M, Ren H, Moriguchi Y, Fujikawa K, Fernandez J	Read publication	2022
Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: The RESET study	Vortioxetine	Thase M, Jacobsen P, Hanson E, Xu R, Tolkoff M, Murthy V	Read publication	2022
Vortioxetine for major depressive disorder in adolescents: 12-week randomized, placebo-controlled, fluoxetine-referenced, fixed-dose study	Vortioxetine	Findling RL, DelBello M, Zuddas A, Emslie GJ, Ettrup A, Petersen ML, Schmidt SN, Rosen M	Read publication	2022

Article	Product	Authors	Publication links	Year	Journal
A large-scale genome-wide gene expression analysis in peripheral blood identifies very few differentially expressed genes related to antidepressant treatment and response in patients with Major Depression Disorder	Vortioxetine	Nøhr AK, Lindow M, Forsingdal A, Demharter S, Nielsen T, Buller R, Moltke I, Vitezic M, Albrechtsen A	Read publication	2021	Neuropsychopharmacology
A Noninterventional Cohort Study Assessing Time to All-Cause Treatment Discontinuation After Initiation of Aripiprazole Once-Monthly or Daily Oral Atypical Antipsychotic Treatment in Patients With Schizophrenia	Aripiprazole	Such P, Bøg M, Kabra M, Jørgensen KT, de Jong-Laird AC	Read publication	2021	The Primary Care Companion for CNS Disorders
Adherence and persistence among patients with major depressive disorder enrolled in the vortioxetine tAccess patient support program	Vortioxetine	Lawrence D, Manjelievskaia J, Chrones L, McCue M, Touya M	Read publication	2021	Current Medical Research & Opinion
Agitation in dementia: real-world impact and burden on patients and the healthcare system	Brexpiprazole	Jones E, Aigbogun MS, Pike J, Berry M, Houle CR, Husbands J	Read publication	2021	Journal of Alzheimer's Disease
An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection	Aripiprazole	Wang Y, Wang X, Harlin M, Larsen F, Panni M, Yildirim M, Madera J, Forbes A, Mustafa N, Ruiz-White I, Raoufinia A	Read publication	2021	Current Medical Research & Opinion
An integrated pharmacokinetic-pharmacodynamic-pharmacoeconomic modelling method to evaluate treatments for adults with schizophrenia	Aripiprazole	Piena M, Houwing N, Kraan C, Wang X, Waters H, Duffy R, Mallikaarjun S, Bennison C	Read publication	2021	PharmacoEconomics
An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants	Brexpiprazole	Dean F. Wong; Suresh Malikaarjun; Arash Raoufinia; Patricia Bricmont; James R. Brašić; Robert D. McQuade; Robert A. Forbes; Tetsuro Kikuchi; Hiroto Kuwabara	Read publication	2021	European Journal of Clinical Pharmacology
Anti-Aβ antibody Aducanumab regulates the proteome of senile plaques and closely surrounding tissue in a transgenic mouse model of Alzheimer’s disease	N/A	Bastrup J, Hansen K, Poulsen T, Kastaniegaard K, Asuni AA, Christensen S, Belling D, Stensballe A, Volbracht C	Read publication	2021	Journal of Alzheimer's Disease
Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: Associations with clinical and treatment outcomes in the AtWoRC Study	Vortioxetine	Chokka P, Ge H, Bougie J, Ettrup A, Clerzius G	Read publication	2021	Therapeutic Advances in Psychopharmacology
Are self-reported and self-monitored adherence good proxies for reaching relevant plasma concentrations? Experiences from a study of anti-depressants in healthy volunteers	Vortioxetine	Larsen KG, Areberg J, Åström DO	Read publication	2021	Clinical Trials
Branning et al. Mental Illness Disclosure in the Workplace: An Opportunity for Improvement. American Health and Drug Benefits	Brexpiprazole	Branning G; Waters HC; Houle CR; Worthy S; Fink B; Hayes K	Read publication	2021	-
Brexpiprazole blocks Posttraumatic stress disorder-like memory and promotes normal fear memory	Brexpiprazole	Ducourneau E-G, Guette C, Perrot D, Mondesir M, Mombereau C, Arnt J, Desmedt A, Piazza P-V	Read publication	2021	Molecular Psychiatry
Cardiovascular Outcomes in Adults With Migraine Treated With Eptinezumab for Migraine Prevention: Pooled Data From Four Double-Blind, Randomized, Placebo-Controlled Studies	Eptinezumab	Smith T, Spierings E, Cady R, Hirman J, Ettrup A, Shen V.	Read publication	2021	-
Changes in antidepressant therapy should be considered early in patients with inadequate response to a first-line agent	Vortioxetine	Bernhard T Baune, Falkai P	Read publication	2021	Australian and New Zealand Journal of Psychiatry
Characterization of the changes in supine blood pressure with long-term use of droxidopa in patients with neurogenic orthostatic hypotension	Droxidopa	Hewitt LA, Lindsten A, Gorny S, Karnik-Henry M, Kymes S, Favit A	Read publication	2021	-
Chronobiologic parameter changes in patients with major depressive disorder and sleep disturbance treated with adjunctive brexpiprazole: an open-label, flexible-dose, exploratory substudy	Brexpiprazole	Krystal AD, Mittoux A, Lindsten A, Baker RA	Read publication	2021	Journal of Affective Disorders
Clinical immunogenicity evaluation of Eptinezumab, a therapeutic humanized monoclonal antibody for the preventive treatment of migraine	Eptinezumab	Pederson S, Biondi D, Allan B, Cady R, Schaeffler B, Baker B, Latham J	Read publication	2021	Frontiers in Immunology
Design and Synthesis of Pyrrolo[2,3 d]pyrimidine-derived Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors using a Checkpoint Kinase 1 (CHK1)-derived Crystallographic Surrogate	N/A	Williamson D, Smith G, Mikkelsen G, Jensen T, Acheson-Dossang P, Badolo L, Bedford S, Chell V, Jen Chen I, Dokurno P, Hentzer M, Newland S, Ray S, Shaw T, Surgenor A, Terry L, Wang Y, Christensen K	Read publication	2021	Journal of Medicinal Chemistry
Droxidopa persistence in neurogenic orthostatic hypotension may be affected by titration approach	Droxidopa	F Amjad, B Polenchar, A Favit	Read publication	2021	International Journal of General Medicine
Early improvement with vortioxetine predicts response and remission: a post hoc analysis of data from a clinical trial conducted in Japan	Vortioxetine	Inoue T, Fujimoto S, Marumoto T, Kitagawa T, Ishida K, Nakajima T, Moriguchi Y, Fujikawa K, Watanabe K	Read publication	2021	-
Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment	Vortioxetine	Fagiolini A, Florea I, Loft H, Christensen MC	Read publication	2021	Journal of Affective Disorders
Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews	Brexpiprazole	Weiss C, Meehan SR, Brown TM, Gupta C, Mørup MF, Thase ME, McIntyre RS, Ismail Z	Read publication	2021	-
Effects of brexpiprazole across symptom domains in patients with schizophrenia: post hoc analysis of short- and long-term studies	Brexpiprazole	Marder S, Meehan SR, Weiss C, Chen D, Hobart M, Hefting N	Read publication	2021	Schizophrenia Bulletin
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial	Eptinezumab	Winner P, McAllister P, Chakhava G, Ailani J, Ettrup A, Josiassen MK, Lindsten A, Mehta L, Cady R	Read publication	2021	JAMA: Journal of the American Medical Association
Efficacy of vortioxetine on anhedonia: results from a pooled analysis of short-term studies in patients with major depressive disorder	Vortioxetine	McIntyre R, Loft H, Christensen MC	Read publication	2021	Neuropsychiatric Disease and Treatment
Establishment of a Human Induced Pluripotent Stem Cell Neuronal Model for Identification of Modulators of α-Synuclein Levels and Aggregation	N/A	Vajhøj C, Schmid B, Bousset L, Melki R, Fog K, Holst B, Stummann TC	Read publication	2021	-
Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review	Brexpiprazole	Brockbank J, Krause T, Moss E, Milthers Pedersen A, Frank Mørup M, Ahdesmäki O, Vaughan J, Brodtkorb T-H	Read publication	2021	Health and Quality of Life Outcomes
Impact of Agitation in Long-Term Care Residents with Dementia in the United States	Brexpiprazole	Fillit H, Aigbogun MS, Gagnon-Sanschagrin P, Cloutier M, Davidson M, Serra E, Guérin A, Baker RA, Houle CR, Grossberg G	Read publication	2021	International Journal of Geriatric Psychiatry
In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole	Brexpiprazole	Sasabe H, Koga T, Furukawa M, Matsunaga M, Sasahara K, Nemoto H, Hashizume K, Ohzone Y, Amunom I, Torii M, Umehara K, Kashiyama E, Takeuchi K	Read publication	2021	Xenobiotica
In vivo and in vitro pharmacokinetic characterization of a novel serotonin-dopamine activity modulator brexpiprazole and a main metabolite in rat, monkey and human	Brexpiprazole	Sasabe H, Koga T, Furukawa M, Matsunaga M, Kaneko Y, Koyama N, Hirao Y, Akazawa H, Kawabata M, Kashiyama E, Takeuchi K.	Read publication	2021	Xenobiotica
Incremental burden of comorbid major depressive disorder in patients with type 2 diabetes or cardiovascular disease: a retrospective claims analysis	Vortioxetine	Kangethe A, Lawrence DF, Touya M, Chrones L, Polson M, Evangelatos T	Read publication	2021	BMC Health Services Research
Long-term safety and tolerability of eptinezumab in patients with chronic migraine: A 2-year, open-label, phase 3 trial	Eptinezumab	Kudrow D, Cady R, Allan B, Pederson S, Hirman J, Mehta L., Schaeffler B.	Read publication	2021	BMC Neurology
Management of Neurogenic Orthostatic Hypotension in Neurodegenerative Disorders: A Collaboration Between Cardiology and Neurology	Droxidopa	F Amjad, S Beinart	Read publication	2021	Neurology and Therapy
Management Strategies for Comorbid Supine Hypertension in Patients With Neurogenic Orthostatic Hypotension	Droxidopa	Isaacson S, Dashtipour K, Mehdirad A, Peltier A	Read publication	2021	Current Neurology and Neuroscience Reports
Monoacylglycerol lipase inhibition in Tourette syndrome. A 12-week randomized, placebo-controlled, study with Lu AG06466	N/A	Kirsten R. Müller-Vahl, Carolin Fremer, Chan Beals, Jelena Ivkovic, Henrik Loft and Christoph Schindler	Read publication	2021	-
New Drug and Biologics Approvals in 2019: A Systematic Analysis of Patient Experience Data in FDA Drug Approval Packages and Product Labels	N/A	Schultz-Knudsen K, Sabaliauskaite U, Hellsten J, Blaedel Lassen A, Vinther Morant A	Read publication	2021	Therapeutic Innovation & Regulatory Science
Nonclinical safety evaluation, pharmacokinetics and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies	N/A	Fjord-Larsen L, Thougaard A, Wegener KM, Christensen J, Larsen F, Schrøder-Hansen LM, Kaarde M, Ditlevsen D	Read publication	2021	-
Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate	Aripiprazole	Such P, Olivares JM, Arias L, Berg MT, Madera J	Read publication	2021	Neuropsychiatric Disease and Treatment
Patient and physician perspectives of depressive symptoms and expectations for treatment outcome: results from a web-based survey	Vortioxetine	Ishigooka J, Hoshino T, Imai T,Yoshida H, Ono M, Ota M, Moriguchi Y, Fujikawa K, Shintani A, Fernandez J	Read publication	2021	Neuropsychiatric Disease and Treatment
Patient expectations and experience of the early phases of antidepressant therapy for major depressive disorder: A qualitative study	Vortioxetine	Baune BT, Florea I, Ebert B, Touya M, Ettrup A, Hadi M, Ren H	Read publication	2021	Neuropsychiatric Disease and Treatment
Patient-Identified Most Bothersome Symptom in Preventive Migraine Treatment With Eptinezumab: A Novel Patient Centered Outcome	Eptinezumab	Lipton R, Dodick D, Ailani J, McGill L, Hirman J, Cady R	Read publication	2021	Headache: The Journal of Head and Face Pain
Personalized prediction of progression in pre-dementia patients based on individual biomarker profile: A development and validation study	N/A	Kühnel L, Bouteloup V, Lespinasse J, Chêne G, Dufouil C, Raket LL	Read publication	2021	-
Phosphodiesterase type 1 inhibition Alters medial prefrontal cortical activity and reward-driven behaviour and Partially reverses neurophysiological deficits in the rat phencyclidine model of schizophrenia	N/A	Hayes J, Laursen B, Eneberg E, Kehler J, Rasmussen L, Langgard M, Bastlund J, Gerdjikov T	Read publication	2021	Neuropsychopharmacology
Pooled analysis of safety information of clinical trials of vortioxetine including Japanese patients with major depressive disorder	Vortioxetine	Osawa M, Nakajima T, Fujimoto S, Ogino Y, Moriguchi Y, Takeshi I	Read publication	2021	-
Predicting time to relapse in patients with schizophrenia according to patients’ relapse history: a historical cohort study using real-world data in Sweden	Brexpiprazole	Jørgensen KT, Bøg M,Kabra M, Simonsen J, Adair M, Jönsson L	Read publication	2021	-
Predictors and trajectories of treatment response to SSRIs in patients suffering from PTSD	Brexpiprazole	Anne Krogh Nøhr, Hans Eriksson, Mary Hobart, Ida Moltke, Raimund Buller, Anders Albrechtsen, Stinus Lindgreen	Read publication	2021	Psychiatry Research
Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study	Aripiprazole	Olivares JM, González-Pinto A, Páramo M	Read publication	2021	European Psychiatry
Prevalence of post-traumatic stress disorder in the United States: a systematic literature review	Brexpiprazole	Schein J, Houle CR, Urganus AL, Jones E, Pike J, Husbands J, Willey CJ	Read publication	2021	-
Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache	Eptinezumab	Marmura MJ, Diener HC, Cowan RP, Tepper SJ, Diamond ML, Starling AJ, Hirman J, Mehta L, Brevig T, Cady R	Read publication	2021	Headache: The Journal of Head and Face Pain
Quantification of in vivo metabolic activity of CYP2D6 genotypes and alleles through population pharmacokinetic analysis of vortioxetine	Vortioxetine	Frederiksen T, Areberg J, Schmidt E, Stage TB, Brosen K	Read publication	2021	Clinical Pharmacology & Therapeutics
Redefining Expectations for Migraine Prevention	Eptinezumab	Cady R, Gottschalk C, Pavlovic J	Read publication	2021	US Neurology
Relationship of subjective cognitive impairment with psychosocial function and relapse of depressive symptoms in patients with major depressive disorder: analysis of longitudinal data from PERFORM-J	Vortioxetine	Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Hammer-Helmich L, Fernandez J	Read publication	2021	Neuropsychiatric Disease and Treatment
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials	Eptinezumab	Smith T, Spierings E , Cady R, Hirman J, Schaeffler B, Werther S, Shen V, Spierling B, Brevig T, Josiassen M, Brunner E, Mehta L, Honeywell L	Read publication	2021	The Journal of Headache and Pain
Safety of switching to brexpiprazole in Japanese patients with schizophrenia: a post-hoc analysis of a long-term open label study	Brexpiprazole	Ishigooka J, Inada K, Niidome K, Aoki K, Kijima Y, Iwashita S, Yamada S	Read publication	2021	Human Psychopharmacology: Clinical and Experimental, Psychiatry and Clinical Neurosciences
Schein et al. Prevalence of post-traumatic stress disorder in the United States: A systematic literature review	Brexpiprazole	Schein J, Houle C, Urganus A, Cloutier M, Patterson-Lomba O, Wang Y, King S, Levinson W, Guerin A, Lefebvre P, Davis LL	Read publication	2021	Current Medical Research & Opinion
Simultaneous Modelling of Alzheimer’s Disease Progression via Multiple Cognitive Scales	N/A	Kühnel L, Berger A-K, Markussen B, Raket L	Read publication	2021	Statistics in Medicine
Systemic administration of Ivabradine, an HCN channel inhibitor, blocks spontaneous absence seizures	N/A	Iacone Y, Morais T, David F, Delicata F, Parri R, Weisser J, Bundgaard C, Vestergaard Klewe I, Thomsen M, Crunelli V, Lőrincz M	Read publication	2021	Epilepsia
The Eptinezumab:CGRP Complex Structure: The Role of Conformational Changes in Binding Stabilization	Eptinezumab	Laurent D, Scalley Kim M, Olland A, White A, Misura K,	Read publication	2021	-
Therapeutic potential of vortioxetine for anxious depression: a post hoc analysis of data from a clinical trial conducted in Japan	Vortioxetine	Inoue T, Fujimoto S, Marumoto T, Kitagawa T, Ishida I, Nakajima T, Moriguchi Y, Fujikawa K, Watanabe K	Read publication	2021	-
Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients	Eptinezumab	Baker B, Schaeffler B, Hirman J, Hompesch M, Peterson S, Smith J	Read publication	2021	Endocrinology, Diabetes & Metabolism
Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection	Aripiprazole	Fitzgerald HM, Shepherd J, Bailey H, Berry M, Wright J, Chen M	Read publication	2021	Neuropsychiatric Disease and Treatment
Two randomized, placebo-controlled double-blind trials and one open-label long-term trial of brexpiprazole for the acute treatment of bipolar mania	Brexpiprazole	Eduard Vieta, Gary Sachs, Denise Chang, Johan Hellsten, Claudette Brewer, Tim Peters Strickland, Nanco Hefting	Read publication	2021	Journal of Psychopharmacology
Using the goal attainment scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open label, multicenter study	Vortioxetine	McCue M, Sarkey S, Eramo A, François C, Parikh SV	Read publication	2021	BMC Psychiatry
Validation of a population pharmacokinetic model of vortioxetine using therapeutic drug monitoring data	Vortioxetine	Frederiksen T, Smith RL, Wollmann BM, Areberg J, Molden E	Read publication	2021	-
Validation of the oxford depression questionnaire: sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting	Vortioxetine	Christensen MC, Fagiolini A, Florea I, Loft H, Cuomo A, Goodwin G	Read publication	2021	Journal of Affective Disorders Reports
Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety and optimal timing of dose adjustment	Vortioxetine	Christensen MC, McIntyre RS, Florea I, Loft H, Fagiolini A	Read publication	2021	CNS Spectrums

Article	Product	Authors	Publication links	Year	Journal
A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study	Vortioxetine	Jacobsen P, Zhong W, Xu R, Nomikos G	Read publication	2020	Journal of Affective Disorders
A PET Occupancy Study of Brexpiprazole at Dopamine D2 and D3 Receptors, Serotonin 5-HT1A and 5-HT2A Receptors, and Serotonin Reuptake Transporters in Subjects With Schizophrenia	Brexpiprazole	Girgis R, Abi-Dargham A, Forbes, A, Slifstein M	Read publication	2020	Neuropsychopharmacology
A Questionnaire-Based Evaluation of the Attitude of European Physicians towards the Use of Antipsychotic Long-Acting Injectables	Aripiprazole	Heres S, Patel M, Bent-Ennakhil N, Sapin C, di Nicola S	Read publication	2020	BMC Psychiatry,European Neuropsychopharmacology
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder	Vortioxetine	Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I	Read publication	2020	Rinsho Yakuri (Japanese Journal of Clinical Pharmacology)
Cardiovascular Disorders Mediated by Autonomic Nervous System Dysfunction	Droxidopa	Mehdirad A, Khemani P	Read publication	2020	Cardiology in Review
Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram	Vortioxetine	Jacobsen PL, Zhong W, Nomikos GG, Affinito J, Cutler AJ, Clayton	Read publication	2020	CNS Spectrums
Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine	Eptinezumab	Houts, C, Wirth R, McGinley J, Cady R, Lipton R,	Read publication	2020	Headache: The Journal of Head and Face Pain
Effect of brexpiprazole on impulsivity in schizophrenia: a task-based functional magnetic resonance imaging study	Brexpiprazole	van Erp TGM, Baker RA, Cox K, Okame T, Kojima Y, Eramo A, Potkin SG	Read publication	2020	Psychiatry Research: Neuroimaging
Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma	Vortioxetine	Christensen MC, Florea I, Loft H, McIntyre RS	Read publication	2020	Journal of Affective Disorders
Efficacy, Tolerability, and Safety of Eptinezumab in Patients with a Dual Diagnosis of Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2	Eptinezumab	Diener HC, Marmura M, Tepper S, Cowan R, Starling A, Diamond M, Hirman J, Mehta L, Brevig T, Sperling B, Cady R	Read publication	2020	Headache: The Journal of Head and Face Pain
Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing	Eptinezumab	Dodick D, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S		2020
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 study	Eptinezumab	Silberstein S, Diamond M, Hindiyeh N, Biondi D, Cady R, Hirman J, Allan B, Pederson S, Schaeffler B, Smith J,	Read publication	2020	The Journal of Headache and Pain
Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study	Eptinezumab	Smith T, Janelidze M, Chakhava G, Cady R, Hirman J, Allan B, Pederson S,Smith J, Schaeffler B,	Read publication	2020	Clinical Therapeutics
Eptinezumab in episodic migraine: The randomized, double-blind, placebo-controlled PROMISE-1 study	Eptinezumab	Ashina M, Saper J, Cady R, Schaeffler B, Biondi D, Hirman J, Pederson S, Allan B, Smith J	Read publication	2020	Cephalalgia
Impact of atypical antipsychotics as adjunctive therapy on psychiatric cost and utilization in patients with major depressive disorder	Brexpiprazole	Yan T, Greene M, Chang E, Houle C, Tarbox M, Broder MS	Read publication	2020	ClinicoEconomics and Outcomes Research
Impact of cognitive symptoms on health-related quality of life and work productivity in Chinese patients with major depressive disorder: results from the PROACT study	Vortioxetine	Wang G, Tan KHX, Ren H, Hammer-Helmich L	Read publication	2020	Neuropsychiatric Disease and Treatment
Improvements in workplace productivity in working patients with major depressive disorder: results from the AtWoRC study	Vortioxetine	Chokka P, Bougie J, Tvistholm AH, Clerzius G, Ettrup A	Read publication	2020	Journal of Occupational and Environmental Medicine
Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: A 7-day randomized, double-blind, placebo-controlled exploratory study	Vortioxetine	Rancans E, Zambori J, Dalsgaard M, Baayen C, Areberg J, Ettrup A, Florea I	Read publication	2020	International Clinical Psychopharmacology
Neurobiology of TRS: Research Roadmap	Lu AF35700	Kane J, Potkin S, Correll C, Agid O, Olfson M, Lindenmayer JP, Marder S, Howes O	Read publication	2020	npj Schizophrenia
Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls	Droxidopa	LeWitt P, Kymes S, Hauser R	Read publication	2020	Aging and Disease
Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine	Droxidopa	Mobarek S	Read publication	2020
Pharmacologic Characterization of ALD403, a Potent Neutralizing Humanized Monoclonal Antibody Against the Calcitonin Gene-Related Peptide	Eptinezumab	Garcia-Martinez L, Raport C, Ojala E, Dutzar B, Anderson K, Stewart E, Kovacevich B, Baker B, Billgren J, Scalley-Kim M, Karasek C, Allison D, Latham J	Read publication	2020	Journal of Pharmacology and Experimental Therapeutics
Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine	Eptinezumab	Baker B, Schaeffler B, Beliveau M, Rubets I		2020	Pharmacology Research & Perspectives
Post hoc analysis of a randomized, placebo-controlled, active-reference 6-week study of brexpiprazole in patients with acute schizophrenia	Brexpiprazole	Marder SR, Eriksson H, Zhao Y, Hobart M	Read publication	2020	Acta Neuropsychiatrica
Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study	Brexpiprazole	Ishigooka J, Usami T, Iwashita S, Kojima Y, Matsuo S		2020
PROMISE–2: Efficacy and safety of eptinezumab in patients with chronic migraine	Eptinezumab	Lipton R, Goadsby P, Smith J, Schaeffler B, Biondi D, Hirman J, Pederson S, Allan B, Cady R	Read publication	2020	Neurology
Psychiatric Cost in Patients with Schizophrenia Treated with Oral Atypical Antipsychotic Therapy	Brexpiprazole	Yan T, Greene M, Chang E, Houle C, Waters HC, Tarbox M, Broder MS	Read publication	2020	Clinical Therapeutics
Real-World Droxidopa or Midodrine Treatment Persistence in Patients With Neurogenic Orthostatic Hypotension or Orthostatic Hypotension	Droxidopa	Kymes S, Jackson K, Sullivan, C, Raj S	Read publication	2020	Autonomic Neuroscience: Basic & Clinical
Real-World Patient Experience with Sexual Dysfunction and Antidepressant use in Depressed Patients: A Cross-Sectional Survey Study	Vortioxetine	Paula L. Jacobsen, Eileen M. Thorley, Christopher Curran, Emil Chiauzzi	Read publication	2020	Neurology, Psychiatry and Brain Research
Reliability and validity of the 6‑item Headache Impact Test in chronic migraine from the PROMISE‑2 study	Eptinezumab	Houts CR, McGinley JS, C, Wirth RJ, Cady R, Lipton RB,	Read publication	2020	Quality of Life Research
Risk of major depressive disorder in Japanese cancer patients: A matched cohort study using employer-based health insurance claims data	Vortioxetine	Akechi T, Mishiro I, Fujimoto S, Murase K	Read publication	2020	Psycho-Oncology
Risk of major depressive disorder in spouses of cancer patients in Japan: a cohort study using health-insurance based claims data	Vortioxetine	Akechi T, Mishiro I, Fujimoto S, Murase K	Read publication	2020	Psycho-Oncology
Successfully treated patients with vortioxetine versus venlafaxine: A simplified cost-effectiveness analysis in Asian patients with major depressive disorder	Vortioxetine	Wang G, Zhao K, Reynaud-Mougin C, Loft H, Ren H, Eriksen H-LF, Ettrup A	Read publication	2020	Current Medical Research & Opinion
Symptoms of major depressive disorder and psychosocial functioning in the different phases of the disease: does the perspective of patients and healthcare providers differ?	Vortioxetine	Christensen MC, Wong J, Baune BT	Read publication	2020	Frontiers in Psychiatry
The Impact of the Food and Drug Administration Antipsychotic Drug Boxed Warning on Psychiatric Medication Use, Health Events, and Quality of Life in Elderly Dementia Patients	Brexpiprazole	Annalisa Rubino, Myrlene Sanon, Michael Ganz, Alex Simpson, Miram Fenton, Sumit Verma, Ann Hartry, Ross Baker, Ruth Duffy, Keva Gwin, Howard Fillit	Read publication	2020	JAMA Network Open
The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: A report on global assessment of functioning and the WHO wellbeing index	Aripiprazole	Schöttle D, Janetzky W, Luedecke D, Beck E, Correll CU, Wiedemann K	Read publication	2020	BMC Psychiatry
Treatment of major depressive disorder in Japanese patients with cancer: a matched cohort study using employer-based health insurance claims data	Vortioxetine	Akechi T, Fujimoto S, Mishiro I, Murase K	Read publication	2020	Clinical Drug Investigation
Using self-reported vocational functioning measures to identify working patients with impaired functional capacity in major depressive disorder	Vortioxetine	Murthy V, Xu R, Zhong W, Harvey P	Read publication	2020	Journal of Affective Disorders

Article	Product	Authors	Publication links	Year	Journal
6-Month Use of Droxidopa for Neurogenic Orthostatic Hypotension	Droxidopa	Francois C, Shibao CA, Biaggioni I, Duhig AM, McLeod K, Ogbonnaya A, Quillen A, Cannon J, Padilla C, Kymes S, Yue B	Read publication	2019	Movement Disorders Clinical Practice
A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as adjunctive therapy in adults with major depressive disorder	Brexpiprazole	Hobart M, Zhang P, Brewer C, Hefting N	Read publication	2019	Journal of Clinical Psychopharmacology
A new principal stratum estimand investigating the treatment effect in patients who would comply, if treated with a specific treatment	Brexpiprazole	Groes Larsen K, Krog Josiassen M	Read publication	2019	Statistics in Biopharmaceutical Research
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder	Vortioxetine	Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I	Read publication	2019	Psychiatry and Clinical Neurosciences
A Systematic Literature Review Identifying Associations Between Outcomes and Quality of Life (QoL) or Health Care Resource Utilisation (HCRU) in Schizophrenia	Lu AF35700	Germain N, Weatherall J, Kymes S, Löf E, Jakubowska A, François C	Read publication	2019	Journal of Medical Economics
Adapting the goal attainment approach for major depressive disorder	Vortioxetine	McCue M, Parikh S, Mucha L, Sarkey S, Cao C, Eramo A, Opler M, Lind B, Francois C	Read publication	2019	Neurology and Therapy
Agitation in patients with dementia: a systematic review of epidemiology and association with severity and course	Brexpiprazole	Anatchkova M, Brooks A, Swett L, Hartry A, Duffy RA, Baker RA, Hammer-Helmich L, Sanon Aigbogun M	Read publication	2019	International Psychogeriatrics
Anti-tau antibody-mediated clearance in mouse microglia cultures requires Fcγ-receptor interaction and functional lysosomes	AF87908 Tau	Andersson CR, Falsig J, Stavenhagen JB, Christensen S, Kartberg F, Rosenqvist N, Finsen B, Pedersen JT	Read publication	2019	Scientific Reports
Assessment of current clinical practices for major depression in Japan using a web-based questionnaire	Vortioxetine	Hori H, Kentaro Y	Read publication	2019	Neuropsychiatric Disease and Treatment
Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5-HT2A receptors in rats	Brexpiprazole	Amada N, Akazawa H, Ohgi Y, Maeda K, Sugino H Kurahashi N, Kikuchi T, Futamura T	Read publication	2019	Neuropsychopharmacology Reports
Burden of Care for Treatment-Resistant Schizophrenia: A Quantitative Caregiver Survey of Experiences, Attitudes and Perceptions	Lu AF35700	Velligan D, Brain C, Bouérat Duvold L, Agid O,	Read publication	2019	Frontiers in Psychiatry
Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine	Vortioxetine	Lachaine J, Beauchemin C, Bibeau J, Patenaude J, Chokka P, Proulx J, Bougie J	Read publication	2019	CNS Spectrums
Characteristics, Burden and Pharmacotherapy of Treatment-Resistant Schizophrenia: Results From a Survey of 204 US Psychiatrists	Lu AF35700	Correll CU, Brevig T, Brain C	Read publication	2019	BMC Psychiatry
Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia	Lu AF35700	Agid O, Baldwin M, Correll C, Howes O, Kane J, Lindenmayer JP, Marder S, Olfson M, Potkin S	Read publication	2019	Journal of Clinical Psychiatry
Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram	Vortioxetine	Jacobsen PL, Zhong W, Nomikos GG, Affinito J, Cutler AJ, Clayton	Read publication	2019	CNS Spectrums
Cognitive symptoms in major depressive disorder: Associations with clinical and functional outcomes in a 6-month, non-interventional, prospective study in China	Vortioxetine	Wang G, Si T-M, Li L-J, Fang Y-R, Wang C-X, Wang L-N, Tan K H X, Ettrup A; Eriksen F H-L, Luo S, Ge L	Read publication	2019	Neuropsychiatric Disease and Treatment
Comparisons of Global Tests on Intersection Hypotheses and Their Application in Matched Parallel Gatekeeping Procedures	Brexpiprazole	Ouyang J, Zhang P, Carroll KJ, Lee J, Koch G	Read publication	2019	Journal of Biopharmaceutical Statistics
Creation and validation of a linear index to measure the health state of patients with depression in automated healthcare databases	Vortioxetine	Touya M, Lamy FX, Tanaescu A, Saragoussi D, Francois C, Wade A, Llorca PM, Lancon C, Falissard B	Read publication	2019	Journal of Market Access & Health Policy
Development of a Classifier to Identify Patients with Probable Lennox–Gastaut Syndrome in Health Insurance Claims Databases Via Random Forest Methodology	Clobazam	Vekeman F, Piña-Garza JE, Cheng WY, Tuttle E, Giguere-Duval P, Oganisian A, Damron J, Duh MS, Shen V, Saurer TB, Montouris GD, Isojarvi J	Read publication	2019	Current Medical Research & Opinion
Differences in perceptions of major depressive disorder symptoms and treatment priorities between patients and health care providers across the acute, post-acute, and remission phases of depression	Vortioxetine	Baune B, Christensen MC	Read publication	2019	Frontiers in Psychiatry
Drug-Drug Interactions With Concomitant Clobazam and Cannabidiol Usage in Refractory Seizures	Clobazam	Tolbert D, Klein P, Gidal B	Read publication	2019	Epilepsy & Behavior
Early Initiation of Long-Acting Injectable Antipsychotic Treatment is Associated with Lower Hospitalization Rates and Healthcare Costs in Patients with Schizophrenia: Real-World Evidence From US Claims Data	Aripiprazole	Munday J, Broder MS, Chang E, Hartry A, Yan TJ, Greene M	Read publication	2019	Current Medical Research & Opinion
Economic burden of relapse/recurrence in patients with major depressive disorder	Vortioxetine	Gauthier G, Mucha L, Shi S, Guerin A	Read publication	2019	Journal of Drug Assessment
Effect of brexpiprazole on agitation and hostility in patients with acute schizophrenia	Brexpiprazole	Citrome L, Ouyang J, Meehan SR, Baker RA, Weiss C	Read publication	2019	Journal of Clinical Psychopharmacology
Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain	Vortioxetine	Yang K-C, Stepanov V, Amini N, Martinsson S, Takano A, Bundgaard C, Bang-Andersen B, Sanchez C, Halldin C, Farde L, Finnema SJ	Read publication	2019	Neuropsychopharmacology
Effects of vortioxetine and escitalopram on electroencephalographic recordings – A randomized, crossover trial in healthy males	Vortioxetine	Nissen TD, Laursen B, Viardot G, l´Hostis P, Danjou P, Sluth LB, Gram M, Bastlund JF, Christensen SR, Drewes AM	Read publication	2019	Neuroscience
Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis	Vortioxetine	Jacobson W, Harvey P, Zhong W, Nomikos G, Olsen CK, Christensen M	Read publication	2019	Current Medical Research & Opinion
Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies	Brexpiprazole	Thase M, Hobart M, Zhang P, Weiss C, Meehan SR	Read publication	2019	Expert Opinion on Pharmacotherapy
Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials	Brexpiprazole	Grossberg G, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, Slomkowski M, Baker RA, McQuade R, Cummings J	Read publication	2019	American Journal of Geriatric Psychiatry
Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma	Vortioxetine	Christensen MC, Florea I, Loft H, McIntyre RS	Read publication	2019	Journal of Affective Disorders
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial	Eptinezumab	Dodick DW, Lipton RB, Silberstein S, Goadsby P4, Biondi D, Hirman J, Cady R, Smith J	Read publication	2019	Cephalalgia
Exploration of treatment-resistant schizophrenia subtypes based on a survey of 204 US psychiatrists	Lu AF35700	Correll CU, Brevig T, Brain C	Read publication	2019	Neuropsychiatric Disease and Treatment
Health-related quality of life outcomes, economic burden and cost associated among diagnosed and undiagnosed depression patients in Japan	Vortioxetine	Yamabe K, Liebert R, Flores N	Read publication	2019	ClinicoEconomics and Outcomes Research
Identifying and Characterizing Treatment-Resistant Schizophrenia in Observational Database Studies	Lu AF35700	Jonsson L, Simonsen J, Brain C, Kymes S, Watson L	Read publication	2019	International Journal of Methods in Psychiatric Research
Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: A 2-week, randomized, double-blind, placebo-controlled study	Vortioxetine	Vieta E, Florea I, Schmidt S N, Areberg J, Ettrup A	Read publication	2019	International Clinical Psychopharmacology
Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder: results from the AtWoRC study	Vortioxetine	Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A	Read publication	2019	CNS Spectrums
Management of Coexistent Neurogenic Orthostatic Hypotension and Supine Hypertension	Droxidopa	Cannom D	Read publication	2019	Journal of Clinical Hypertension
Management of Depression in Adolescents in Japan	Escitalopram	Saito T, Reines E, Florea I, Dalsgaard M	Read publication	2019	Journal of Child and Adolescent Psychopharmacology
Medication adherence, health service use, and costs in patients with major depressive disorder initiating adjunctive antipsychotic treatment	Brexpiprazole	Broder MS, Greene M, Yan T, Chang E, Hartry A, Yermilov I	Read publication	2019	Clinical Therapeutics
Neurogenic Orthostatic Hypotension: A Nonmotor Symptom of Parkinson Disease	Droxidopa	Low P, Cutsforth-Gregory J	Read publication	2019	Neurology and Therapy
Open-label, Multicenter, Phase 3 Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-moderate Alzheimer’s Disease	Idalopirdine	Frölich L, Alireza A, Ballard C, Tariot P, Molinuevo JL, Boneva N, Geist M, Raket L, Cummings J	Read publication	2019	Journal of Alzheimer's Disease
Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls	Droxidopa	LeWitt P, Kymes S, Hauser R	Read publication	2019	Aging and Disease
Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial	Vortioxetine	Jacobsen P, Zhong W, Nomikos G, Clayton A	Read publication	2019	The Journal of Sexual Medicine
Patient attitudes towards and goals for MDD treatment: A survey study	Vortioxetine	McNaughton E, Granskie J, Curran C, Opler M, Sarkey S, Mucha L, Eramo A, Francois C, Webber-Lind B, McCue M	Read publication	2019	Patient Preference and Adherence
Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study	Vortioxetine	Haro JM, Hammer-Helmich L, Saragoussi D, Ettrup A, Larsen KG	Read publication	2019	Neuropsychiatric Disease and Treatment
Pharmacokinetics and safety of vortioxetine in the Chinese population	Vortioxetine	Miao J, Wang G, Hou J, Areberg J, Zhao Y, Højer AM, Ettrup A	Read publication	2019	Advances in Therapy
Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide	Eptinezumab	Moldovan Loomis C, Dutzar B, Ojala EW, Hendrix L, Karasek C, Scalley-Kim M, Mulligan J, Fan P, Billgren J, Rubin V, Boshaw H, Kwon G, Marzolf S, Stewart E, Jurchen D, Pederson SM, Perrino McCulloch L, Baker B, Cady RK, Latham JA, Allison D, Garcia-Martinez LF	Read publication	2019	Journal of Pharmacology and Experimental Therapeutics
Pharmacometrics of Clobazam in Pediatrics: Prediction of Effective Clobazam Doses for Dravet Syndrome	Clobazam	Tolbert D, Chu H-M, Ette EI	Read publication	2019	Epilepsy Research
Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis	Vortioxetine	Liguori C, Ferini-Strambi L, Izzi F, Mari L, Manfredi N, D'Elia A, Mercuri NB, Placidi F	Read publication	2019	British Journal of Clinical Pharmacology
Psychometric validation of Japanese version of Alcohol Quality of Life Scale (AQoLS) in the treatment of patients with alcohol use disorder – a non-interventional, prospective, longitudinal, multi-site cohort study	Nalmefene	Higuchi S, Moriguchi Y, Tan KHX	Read publication	2019	Quality of Life Research
Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study	Aripiprazole	Mustafa S, Bougie J, Miguelez M, Clerzius G, Rampakakis E, Proulx J, Malla A	Read publication	2019	BMC Psychiatry
Relationship of cognitive impairment with depressive symptoms and psychosocial function in patients with major depressive disorder: cross sectional analysis of baseline data from PERFORM-J	Vortioxetine	Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Tan K, Hammer-Helmich L, Fernandez J	Read publication	2019	Journal of Affective Disorders
Results and validation of an index to measure health state of patients with depression in automated healthcare databases	Vortioxetine	Lamy FX, Falissard B, Francois C, Lancon C, Llorca PM, Tanaescu A, Touya M, Verpillat P, Wade A, Saragoussi D	Read publication	2019	Journal of Market Access & Health Policy
Results of a Real-World Study of Vortioxetine in Patients with Major Depressive Disorder in South East Asia (REVIDA): Subgroup Analysis of Malaysian Patients	Vortioxetine	Chin CN, Azhar, Au YKC, Chong MSwee Woon, Yen TH, Yeoh BBD, Yap CH, Ku RKA, Keira JH	Read publication	2019	Malaysian Journal of Psychiatry
Role of Nurses and Nurse Practitioners in the Recognition, Diagnosis, and Management of Neurogenic Orthostatic Hypotension	Droxidopa	Biswas D, Karabin B, Turner D	Read publication	2019	International Journal of General Medicine
Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials.	Vortioxetine	Mahableshwarkar A, Jacobsen P, Affinito J, Reines E, Xu J, Nomikos G	Read publication	2019	CNS Spectrums
Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies	Aripiprazole	Madera JJ, Such P, Zhao C, Baker RA	Read publication	2019	Neuropsychiatric Disease and Treatment
The effect of aripiprazole once monthly on personal and social functioning: Post hoc analyses of acute and long-term studies	Aripiprazole	Peters-Strickland T, Baker RA, Such P, Zhang P, Madera JJ	Read publication	2019	Neuropsychiatric Disease and Treatment
The patient perspective on cognitive symptoms in major depressive disorder: a retrospective database and prospective survey analysis	Vortioxetine	Chiauzzi E, Drahos J, Sarkey S, Curran C, Wang V, Tomori D	Read publication	2019	Journal of Participatory Medicine
Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine	Vortioxetine	Nierenberg AA, Loft H, Olsen CK	Read publication	2019	Journal of Affective Disorders
Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic Hypotension) in a Patient With Cardiovascular Disease and Parkinson Disease: A Case Report	Droxidopa	McCullough P	Read publication	2019	Cardiology and Therapy
Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis	Brexpiprazole	Sanon Aigbogun M, Stellhorn R, Hartry A, Baker RA, Fillit H	Read publication	2019	BMC Neurology
Use of Droxidopa for the Long-Term Treatment of Neurogenic Orthostatic Hypotension	Droxidopa	Hewitt LA, Raj S	Read publication	2019	European Heart Journal
Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment	Aripiprazole	Madera JJ, Such P, Zhang P, Baker RA, Grande I	Read publication	2019	Neuropsychiatric Disease and Treatment
Using self-reported vocational functioning measures to identify working patients with impaired functional capacity in major depressive disorder	Vortioxetine	Murthy V, Xu R, Zhong W, Harvey P	Read publication	2019	Journal of Affective Disorders
Utility of Autonomic Testing for the Efficient Diagnosis and Effective Pharmacologic Management of Neurogenic Orthostatic Hypotension	Droxidopa	Suleman, A; Bin Alam, S; Almardini W	Read publication	2019	BMJ Case Reports
Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized double-blind, placebo-controlled proof-of-concept study	Vortioxetine	Biederman J, Lindsten A, Sluth L B, Petersen M L, Ettrup A, Eriksen H-L F, Fava M	Read publication	2019	Journal of Psychopharmacology
Wearable Technology for High-Frequency Cognitive and Mood Assessment in Major Depressive Disorder: Longitudinal Observational Study.	Vortioxetine	Cormack F, McCue M, Taptiklis N, Skirrow C, Glazer E, Panagopoulos E, van Schaik TA, Fehnert B, King J, Barnett JH	Read publication	2019	JMIR Mental Health

Publications

Publications Co-Authored by Lundbeck Scientists

2023

2022

2021

2020

2019